Investigational BACE inhibitors for the treatment of Alzheimer’s disease
The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Introduction : The amyloid hypothesis of Alzheimer's disease (AD) states that brain accumulation of amyloid-β (Aβ) oligomers and soluble aggregates represents the major causal event of the disease. Several small organic molecules have been synthesized and developed to inhibit the enzyme (β-site amyloid precursor protein cleaving enzyme-1 or BACE1) whose action represents the rate-limiting step in Aβ production. Areas covered : We reviewed the pharmacology and clinical trials of major BACE1 inhibitors. Expert opinion : In transgenic mouse models of AD, BACE1 inhibitors dose-dependently lower Aβ levels in brain and cerebrospinal fluid (CSF) but the evidence for attenuation or reversal cognitive or behavioral deficits is very scanty. In AD patients, BACE1 inhibitors robustly lower plasma and CSF Aβ levels and reduce brain plaques but without cognitive, clinical, or functional benefit. To date, seventeen BACE1 inhibitors have failed in double-blind, placebo-controlled clinical trials in patients with mild-to-moderate or prodromal AD, or in cognitively normal subjects at risk of developing AD. Several of these studies were prematurely interrupted due to toxicity or cognitive and behavioral worsening compared to placebo-treated patients. Elenbecestat, the last BACE1 inhibitor remaining in late clinical testing for AD, was recently discontinued due to safety concerns.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elenbecestat (15, E2609), a fourth-generation BACE1 inhibitors, was among the last BACE1 inhibitors to reach phase III clinical trials.448”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [448]
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease
Kivipelto, M., Mangialasche, F., & Ngandu, T. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0070-3 · Cited by 1,173
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Self-citationElevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
Research works printed but not linked: 6
- Vassar R, 2019, J Prev Alzheimers Dis, 6, 78
- Strobel G, 2019, Alzheimer Res Forum, 17
- Lo AC, 2018, J Prev Alzheimers Dis, 5, S37
- Shugart J, 2019, Alzheimer Res Forum, 12
- Caouette D Eisai and Biogen to discontinue phase III clinical studies of BACE inhibitor elenbecestat in early Alzheimer’s disease. Eisai’s press release;2019 Sept 13.
- Schneeberger A, 2015, J Prev Alzheimers Dis, 2, 103
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
“Several of these studies were prematurely stopped due to toxic effects or cognitive and behavioral decline compared to placebo-treated patients (Imbimbo and Watling, 2019; Suzuki et al., 2017).”
InfluentialTherapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Wang, W., Zhou, Q., Jiang, T., Li, S., Ye, J., Zheng, J., Wang, X., Liu, Y., Deng, M., Ke, D., et al. (2021) · Theranostics · doi:10.7150/thno.55680 · Cited by 242
“reducing Aβ production by β-/γ-secretase inhibitors [6, 7], removing Aβ by promoting its degradation or antibodies [8, 9].”
BackgroundAlzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
“It is well known that glial cells, the particular astrocytes, play a critical role in the neuropathology of different neurodegenerative conditions [71].”
BackgroundNovel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Yu, T.-W., Lane, H.-Y., & Lin, C.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158208 · Cited by 176
“Elenbecestat BACE1 inhibitor MCI to moderate AD Phase III Lack of efficacy, nightmare [26,27]”
BackgroundNewton, S. E. B., Lloreda, C. L., Gannon, P. J., Akay, C., & Jordan‐Sciutto, K. L. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz129 · Cited by 152
“Additionally, BACE2 is largely nonneuronal, but highly homologous to BACE1, and thus some of the detrimental effects of BACE1 inhibition may be accounted for by the offtarget effects on BACE2, as all thus far tested molecules have not been selective between the 2 isoforms (185, 188, 192).”
BackgroundBurns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00043-0 · Cited by 130
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer's Disease · doi:10.1155/2022/9343514 · Cited by 115
“The trials of BACE inhibitors have also failed to show clinical significance, and a trial was stopped due to safety concerns [56].”
BackgroundSperling, R., Henley, D., Aisen, P. S., Raman, R., Donohue, M. C., Ernstrom, K., Rafii, M. S., Streffer, J., Shi, Y., Karcher, K., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4857 · Cited by 112
García-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
“However, the trials were stopped in phase III due to cognitive and functional worsening in patients treated with these drugs, as well as the development of adverse effects [106].”
BackgroundSingh, N., Das, B., Zhou, J., Hu, X., & Yan, R. (2022) · Science Advances · doi:10.1126/sciadv.abo3610 · Cited by 95
“However, despite an appreciable reduction in A load, patients with AD taking these drugs failed to show cognitive benefits (5), and rapid loss of hippocampal volume was also noted (6).”
BackgroundCritical Appraisal of Amyloid Lowering Agents in AD
Decourt, B., Boumelhem, F., Pope, E. D., Shi, J., Mari, Z., & Sabbagh, M. N. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01125-y · Cited by 85
Pasieka, A., Panek, D., Szałaj, N., Espargaró, A., Więckowska, A., Malawska, B., Sabaté, R., & Bajda, M. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00235 · Cited by 78
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77
BACE-1 inhibition facilitates the transition from homeostatic microglia to DAM-1
Singh, N., Benoit, M., Zhou, J., Das, B., Dávila-Velderrain, J., Kellis, M., Tsai, L., Hu, X., & Yan, R. (2022) · Science Advances · doi:10.1126/sciadv.abo1286 · Cited by 74
“However, despite a substantial reduction in A load, human clinical trials have failed to demonstrate improvements in cognitive functions in patients with AD due to neuronal and synaptic toxicity (7).”
BackgroundImbimbo, B. P., Ippati, S., Watling, M., & Imbimbo, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106631 · Cited by 65
Self-citationReview on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 72
Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Checler, F., Afram, E., Pardossi-Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 59
“6% Aβ reduction in brain PET scan (florbetaben and florbetapir respectively) at 50 mg Discontinued in 2019 (prodromal, mild to moderate AD patients) Weight loss, skin rashes and neuropsychiatric adverse events (224) (225) JB C R EV EW S: γ-Seetase:a bene ficialCinactivating ezym e J.”
BackgroundAlzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 84
Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease
Xiong, Y., & Lim, C. (2021) · Brain Sciences · doi:10.3390/brainsci11091211 · Cited by 62
“However, inhibition of γ-secretase causes severe side effects because of the extensive functions of γ-secretase in our body [19,20] and development of a β-secretase inhibitor is challenging [21].”
BackgroundAxonal regeneration and sprouting as a potential therapeutic target for nervous system disorders
Marshall, K. L., & Farah, M. H. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308077 · Cited by 65
“BACE1 inhibitors have been under extensive development for decades (Imbimbo and Watling, 2019).”
BackgroundDiagnosis and Treatment of Alzheimer’s Disease:
Bomasang-Layno, E., & Bronsther, R. (2021) · Delaware Journal of Public Health · doi:10.32481/djph.2021.09.009 · Cited by 74
Review of PINK1-Parkin-mediated mitochondrial autophagy in Alzheimer's disease
Zhou, T.-Y., Ma, R., Li, J., Zou, B., Yang, H., Ma, R.-Y., Wu, Z., Li, J., & Yao, Y. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176057 · Cited by 46
Potential Role of Venular Amyloid in Alzheimer’s Disease Pathogenesis
Morrone, C. D., Bishay, J., & McLaurin, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061985 · Cited by 47
Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease
Nordvall, G., Lundkvist, J., & Sandin, J. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1279740 · Cited by 44
Therapeutic Potential and Molecular Mechanisms of Echinacoside in Neurodegenerative Diseases
Li, J., Yu, H., Yang, C. H., Ma, T., & Dai, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841110 · Cited by 51
“…the activation of ERS related pathways Zhang Y et al. (2017) MPTP model mice improves mitochondrial dysfunction mitochondria complex reduce equivalents Iverson (2013) SH-SY5Y cell line improves mitochondrial dysfunction mitochondria complex attenuate cell damage and reverse complex Ⅰ by…”
BackgroundMachauer, R., Lueoend, R., Hurth, K., Veenstra, S. J., Rueeger, H., Voegtle, M., Tintelnot-Blomley, M., Rondeau, J.-M., Jacobson, L. H., Laue, G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01300 · Cited by 40
Current druggable targets for therapeutic control of Alzheimer's disease
Gupta, G. L., & Samant, N. P. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106549 · Cited by 41
Javed, M. A., Bibi, S., Jan, M. S., Ikram, M., Zaidi, A., Farooq, U., Sadiq, A., & Rashid, U. (2022) · RSC Advances · doi:10.1039/d2ra04183a · Cited by 37
Satir, T. M., Agholme, L., Karlsson, A., Karlsson, M., Karila, P., Illes, S., Bergström, P., & Zetterberg, H. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00635-0 · Cited by 33
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Imbimbo, B. P., Lozupone, M., Watling, M., & Panza, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1795127 · Cited by 31
Self-citationGatti, M., Zavatti, M., Beretti, F., Giuliani, D., Vandini, E., Ottani, A., Bertucci, E., & Maraldi, T. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2785343 · Cited by 33
“Finally we investigated the modulation of intracellular AD markers, by using the antibody 6E10, specific for human Amyloid precursor protein (APP), Aβ oligomers [29], and molecules generated from cleavage of APP by secretases [30], and anti-Tau phosphorylated in Serine 422 [31], a pathological epitope and one of the m…”
MethodDiscovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor
McKinzie, D. L., Winneroski, L. L., Green, S. J., Hembre, E. J., Erickson, J. A., Willis, B. A., Monk, S. A., Aluise, C. D., Baker, T. K., López, J. E., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00489 · Cited by 32
Pasieka, A., Panek, D., Jończyk, J., Godyń, J., Szałaj, N., Latacz, G., Tabor, J., Mezeiová, E., Chantegreil, F., Dias, J., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113397 · Cited by 31
TUFM is involved in Alzheimer’s disease-like pathologies that are associated with ROS
Zhong, B., Zhou, G., Song, L., Wen, Q., Deng, X., Ma, Y., Hu, L., & Chen, G. (2021) · The FASEB Journal · doi:10.1096/fj.202002461r · Cited by 28
Pi, T., Wei, S., Jiang, Y., & Shi, J. (2021) · Behavioural Neurology · doi:10.1155/2021/6683318 · Cited by 32
Alfei, S., & Zuccari, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020844 · Cited by 28
Syeda, T., & Cannon, J. R. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22694 · Cited by 31
Reiss, A. B., Montufar, N., DeLeon, J. R., Pinkhasov, A., Gomolin, I. H., Glass, A. D., Arain, H. A., & Stecker, M. M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000320 · Cited by 28
Lin, L., Li, C., Li, T., Zheng, J., Shu, Y., Zhang, J., Shen, Y., & Ren, D. (2023) · Food Frontiers · doi:10.1002/fft2.210 · Cited by 31
Therapeutic potential of puerarin against cerebral diseases: From bench to bedside
Liu, T., Su, K., Cai, W., Ao, H., & Li, M. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175695 · Cited by 26
Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?
Reiss, A. B., Glass, A. D., Wısnıewskı, T., Wolozin, B. L., Gomolin, I. H., Pinkhasov, A., Leon, J. D., & Stecker, M. M. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001297 · Cited by 27
Therapeutic Strategies Targeting Amyloid-β Receptors and Transporters in Alzheimer’s Disease
Lao, K., Zhang, R., Luan, J., Zhang, Y., & Gou, X. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200851 · Cited by 29
“-secretase [117–119], or reducing A (cid:2) levels through immunotherapy [120, 121].”
Potential Role of Phenolic Extracts of Mentha in Managing Oxidative Stress and Alzheimer’s Disease
Hanafy, D. M., Burrows, G. E., Prenzler, P. D., & Hill, R. A. (2020) · Antioxidants · doi:10.3390/antiox9070631 · Cited by 33
“, the proper selection of doses and drug interactions) [53].”
BackgroundInfluentialNatural Products from Plants and Algae for Treatment of Alzheimer’s Disease: A Review
Klose, J., Griehl, C., Roßner, S., & Schilling, S. (2022) · Biomolecules · doi:10.3390/biom12050694 · Cited by 23
What have we learned from past failures of investigational drugs for Alzheimer’s disease?
Imbimbo, B. P., & Watling, M. I. L. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2017881 · Cited by 26
“Detrimental effects of BACE1 inhibitors have even been seen in cognitively normal subjects at risk of developing AD [24,33].”
BackgroundSelf-citationOuknin, M., Aghraz, A., Chibane, M., Boumezzourh, A., Costa, J., & Majidi, L. (2021) · Journal of Food Measurement & Characterization · doi:10.1007/s11694-021-00952-4 · Cited by 27
Liu, N., Haziyihan, A., Zhao, W. G., Chen, Y., & Chao, H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00434-9 · Cited by 28
“Drugs that regulate Aβ secretion include the β-secretase inhibitor Lanabecestat [77, 78] and the γ-secretase inhibitor Semagacestat [62], which can inhibit the BACE1 enzyme and the γ-secretase enzyme complex, respectively, further reducing Aβ production [62].”
BackgroundUgbaja, S. C., Lawal, I. A., Kumalo, H. M., & Lawal, M. M. (2021) · Current Drug Targets · doi:10.2174/1389450122666210809100050 · Cited by 22
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease
Lozupone, M., Berardino, G., Mollica, A., Sardone, R., Dibello, V., Zupo, R., Lampignano, L., Castellana, F., Bortone, I., Stallone, R., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2095261 · Cited by 23
“with β-site amyloid precursor protein cleaving enzyme-(BACE)inhibitors [27], inhibiting Aβ deposition with anti-aggregation”
InfluentialTargets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 19
The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice
Dekeryte, R., Franklin, Z. J., Hull, C. E., Croce, L., Kamli-Salino, S., Helk, O., Hoffmann, P. A., Yang, Z., Riedel, G., Delibegović, M., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166149 · Cited by 20
“Consequently, a better understanding of the precise pharmacokinetics of effective BACE1 inhibition to abolish Aβ toxicity, the contribution of other BACE1 substrates, as well as signalling pathways affected in other tissues would seem essential to avoid failing clinical trials with BACE1 inhibitors [30].”
BackgroundRepurposing Antihypertensive Drugs for the Management of Alzheimer’s Disease
Law, C. S. W., & Yeong, K. Y. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200312114223 · Cited by 18
“In fact, some of the trials were halted due to toxicity or safety concerns and cognitive worsening in the patients as compared to placebo [9].”
BackgroundJanssens, J., Hermans, B., Vandermeeren, M., Barale-Thomas, E., Borgers, M., Willems, R., Meulders, G., Wintmolders, C., den Bulck, D. V., Bottelbergs, A., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105365 · Cited by 20
“clinical development for BACE inhibitors (Hampel et al., 2020; Imbimbo and Watling, 2019).”
Experimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 20
“To date, all BACE inhibitors which have been evaluated in large- scale AD trials have failed (Imbimbo & Watling, 2019; Liu et al., 2019).”
BackgroundAccelerating Alzheimer’s disease drug discovery and development: what’s the way forward?
Imbimbo, B. P., Ippati, S., Watling, M. I. L., & Balducci, C. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1887132 · Cited by 18
“Typical examples are BACE1 inhibitors that dramatically reduced CSF Aβ levels, even while worsening cognition, behavior and even brain atrophy, rather than improving them [19].”
BackgroundSelf-citationProphylactic evaluation of verubecestat on disease‐ and symptom‐modifying effects in 5XFAD mice
Oblak, A. L., Cope, Z. A., Quinney, S. K., Pandey, R. S., Biesdorf, C., Masters, A. R., Onos, K. D., Haynes, L., Keezer, K. J., Meyer, J. A., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12317 · Cited by 15
Lucero, E., Freund, R. K., Smith, A. N., Johnson, N. R., Dooling, B. R., Sullivan, E. J., Prikhodko, O., Ahmed, M. M., Bennett, D. A., Hohman, T. J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105288 · Cited by 14
“Many current experimental treatments for AD have focused on reducing Ab production or on increasing the clearance of Ab plaques [reviewed in (Demattos et al., 2012; Imbimbo and Watling, 2019; Jeremic et al., 2021)].”
Guo, Y., Cai, C., Zhang, B., Tan, B., Tang, Q., Lei, Z., Qi, X., Chen, J., Zheng, X., Zi, D., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00146-7 · Cited by 18
Barber, J., Sikakana, P., Sadler, C., Baud, D., Valentin, J., & Roberts, R. A. (2020) · Toxicology Research · doi:10.1093/toxres/tfaa106 · Cited by 16
“For instance the inhibition of renin in hypertension treatment [27], human immunodeficiency virus (HIV) aspartyl protease inhibitors for autoimmune deficiency syndrome (AIDS) [28], CatD targeting antibodies in breast cancer [29], and BACE1 inhibitors for Alzheimer’s disease [30].”
BackgroundKim, J., Jeon, H., Kim, H. Y., & Kim, Y. S. (2023) · ChemBioChem · doi:10.1002/cbic.202300328 · Cited by 17
American Ginseng for the Treatment of Alzheimer’s Disease: A Review
Shan, M., Bai, Y., Fang, X., Lan, X., Zhang, Y., Cao, Y., Zhu, D., & Luo, H. (2023) · Molecules · doi:10.3390/molecules28155716 · Cited by 16
BACE1 inhibitors: A promising therapeutic approach for the management of Alzheimer’s disease
Arya, R., Jain, S., Paliwal, S., Madan, K., Sharma, S. K., Mishra, A., Tiwari, P. K., & Kadiri, S. K. (2024) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_192_24 · Cited by 20
The role and therapeutic implication of protein tyrosine phosphatases in Alzheimer’s disease
Zhao, X., Li, X., She, L., Li, L., Huang, P. C., & Liang, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113188 · Cited by 17
Neuroprotective Activity of Mentha Species on Hydrogen Peroxide-Induced Apoptosis in SH-SY5Y Cells
Hanafy, D. M., Prenzler, P. D., Burrows, G. E., Gurusinghe, S., Thejer, B. M., Obied, H. K., & Hill, R. A. (2020) · Nutrients · doi:10.3390/nu12051366 · Cited by 16
“toxicity or cognitive worsening compared to placebo-treated patients [4,26].”
InfluentialZaręba, P., Łątka, K., Mazur, G., Gryzło, B., Pasieka, A., Godyń, J., Panek, D., Skrzypczak-Wiercioch, A., Höfner, G. C., Latacz, G., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115832 · Cited by 15
Jayan, J., Lee, J., Kumar, S., Manoharan, A., Anishma, P. N., Jauhari, R., Abdelgawad, M. A., Ghoneim, M. M., Ebrahim, H. A., Zachariah, S. M., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c05719 · Cited by 15
Chen, Q., Wang, J., Gao, Y., Wang, Z., Gao, X., & Yan, P. (2023) · Nutrients · doi:10.3390/nu15234878 · Cited by 14
“Therefore, inhibiting the expression of the BACE gene can prevent the A β pathway, thereby achieving the therapeutic effect of AD [45].”
BackgroundIdentification of novel Aβ-LilrB2 inhibitors as potential therapeutic agents for Alzheimer's disease
Lao, K., Zhang, R., Dai, Y., Luan, J., Guo, N., Xu, X., Zhang, Y., & Gou, X. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103630 · Cited by 11
Ma, W., Chen, A.-F., Xie, X., & Huang, Y. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108342 · Cited by 13
DEAD-Box Helicase 17 Promotes Amyloidogenesis by Regulating BACE1 Translation
Liu, Y., Zhou, G., Li, S., Wen, Q., Xie, S., Chen, L., Wang, L., Xie, X., Chen, X., Pu, Y., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13050745 · Cited by 12
“Previous studies have shown that the expression of BACE1 can be regulated at several levels, including gene transcription, translation, and protein degradation [9,44,45].”
Ohno, M. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12174 · Cited by 10
Youn, K., & Jun, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910507 · Cited by 10
“The C-terminal fragment is then cleaved by γ -secretase to release A β , causing oxidative stress, mitochondrial dysfunction, and neuroinflammation [3,4].”
BackgroundOhno, M. (2023) · Frontiers in Dementia · doi:10.3389/frdem.2023.1161875 · Cited by 10
“The major concern over prior clinical trials is that high-dose BACE1 inhibitor strategies tested to date, which often achieved >70% Aβ reduction, suffered from the side effects, especially, unexpected cognitive worsening at the highest dosing of most BACE1 inhibitors in prodromal AD (Imbimbo and Watling, 2019; McDade…”
BackgroundInfluentialPan, L., He, Q., Wu, Y., Zhang, N., Cai, H., Yang, B., Wang, Y., Li, Y., & Wu, X. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128543 · Cited by 10
Willis, B. A., Lowe, S. L., Monk, S. A., Cocke, P. J., Aluise, C. D., Boggs, L. N., Borders, A. R., Brier, R. A., Dean, R. A., Green, S. J., et al. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210037 · Cited by 8
“These results suggest that LY3202626 is substantially more potent than other BACE1 inhibitors for which clinical data have been reported [22, 23].”
BackgroundFronza, M. G., Sacramento, M., Alves, D. A. C., Praticò, D., & Savegnago, L. (2022) · Neurochemical Research · doi:10.1007/s11064-021-03514-8 · Cited by 9
“Although BACE inhibitors were effective in reducing Aβ, recently several clinical trials have been suspended due to the lack of effect on cognitive function and potential brain shrinkage [28, 29].”
BackgroundLi, S., Zhao, H., Li, J., Hao, J., & Yu, H. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1754917 · Cited by 8
“While some new medications for AD are currently undergoing clinical trials, none has exhibited the ability to slow or stop the progression of the disease, suggesting that the medical need for disease-modifying therapy for AD has not been met (Imbimbo & Watling, 2019).”
BackgroundNatural Products with BACE1 and GSK3β Inhibitory Activity
Prado, P. C., Lima, J. A., Hamerski, L., & Rennó, M. N. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666221118113923 · Cited by 7
Navarro-Gómez, N., Valdes-Gonzalez, M., Garrido-Suárez, B. B., & Garrido, G. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.2 · Cited by 7
“This molecule has a higher affinity for BACE 1 than BACE 2 (29).”
BackgroundArakawa, R., Takano, A., Stenkrona, P., Stepanov, V. A., Nag, S., Jahan, M., Grybäck, P., Bolin, M., Chen, L. M., Zhang, L., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04739-5 · Cited by 7
Mei, J., Xu, W., Gao, W., Wang, C., Guan, Y., Ahmad, S., & Ai, H. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp02746e · Cited by 7
Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study
Thomas, J., & WILSON, S. K. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.3522.1 · Cited by 7
Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact
Schreiner, T. G., & Popescu, B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245986 · Cited by 5
“The results showed a decrease in Aβ brain accumulation [105], but without a real improvement in memory and behavioral deficits [106].”
Backgroundβ-Secretase as a Primary Drug Target of Alzheimer Disease: Function, Structure, and Inhibition
Verma, S. K., & Paramanick, D. (2023) · Springer eBooks · doi:10.1007/978-981-99-2657-2_5 · Cited by 5
Novel therapeutic approaches for targeting Alzheimer’s disease
Khodakiya, A., Chaudhary, S., Chaudhary, A., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00020-0 · Cited by 5
Ohno, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231451 · Cited by 5
“More serious side effects in prior clinical trials with high-dose strategies, which often achieved > 70% A (cid:2) reduction, include unexpected cognitive worsening noted at the highest dosing of most BACE1 inhibitors in prodromal AD individuals [4–6].”
Huang, Y., Chan, H., Khoo, J.-Y., Chan, M.-L., Bender, D. A., Ponnusamy, V. K., Belaidi, A. A., & Ke, L. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106104 · Cited by 4
Alzheimer’s Disease: Treatment Today and Tomorrow
Gorthi, S. P., & Gupta, D. (2023) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_254_23 · Cited by 5
“[18] Thus, despite reducing the A β levels, these drugs were worsening cognition.”
Panigrahy, S., Sikder, A., Amulya, E., Shah, S., Khairnar, P., Saraf, S., & Srivastava, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105325 · Cited by 5
Chintamaneni, P. K., Pindiprolu, S. K. S. S., Krishnamurthy, P. T., & Varshini, M. S. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_12 · Cited by 3
Kumari, A., & Zeng, X.-A. (2026) · Nutrients · doi:10.3390/nu18060907 · Cited by 6
Wang, M., & Liu, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-58584-9 · Cited by 5
Ongtanasup, T., & Eawsakul, K. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/5528793 · Cited by 5
Latli, B., Hrapchak, M. J., Reeves, J. T., Lee, H., & Song, J. J. (2023) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4022 · Cited by 3
Tarif, A. M. M., Huhe, H., & Ohno, M. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06525-9 · Cited by 4
“This adverse effect occurred at the highest dosage of multiple inhibitor drugs that often achieved > 70% Aβ reductions, most likely reflecting side effects associated with BACE1 over-inhibition (Imbimbo and Watling 2019; McDade et al. 2021; Bazzari and Baz-zari 2022).”
InfluentialSingh, A., Maker, M., Prakash, J., Tandon, R., & Mitchell, C. S. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230174 · Cited by 3
“During previous clinical trials, BACE1 inhibitors were able to achieve up to 80–90% A (cid:2) reductions in cerebrospinal fluid; yet, these therapies failed to significantly demonstrate slowing of the cognitive decline [50].”
BackgroundTautou, M., Eddarkaoui, S., Descamps, F., Larchanché, P.-E., Bakali, J. E., Goveas, L. M., Dumoulin, M., Lamarre, C., Blum, D., Buée, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.679335 · Cited by 5
“Few studies involving ß-secretase inhibitors were shown to reverse or attenuate the behavioral and memory deficits in transgenic mouse models of AD (Imbimbo and Watling, 2019).”
Background
Metadata
- Authors
- Imbimbo, B. P., & Watling, M.
- Affiliations
- Chiesi (Italy) (IT)
- CNS & Pain Department, TranScrip Partners, Reading, UK
- Corresponding author
- Imbimbo, Bruno P.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2019-10-29
- Volume
- 28
- Issue
- 11
- Pages
- 967-975
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2982501787
- Cited by
- 132
- References
- 61
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 21 · 2023: 22 · 2022: 20 · 2021: 38 · 2020: 14
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- BACE1 inhibitors, Alzheimer's disease, amyloid hypothesis, amyloid-beta, amyloid plaques, cerebrospinal fluid amyloid-beta, clinical trial failure, drug safety, cognitive decline, transgenic mouse model
- MeSH terms
- Drug Development, Alzheimer Disease, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, Mice, Transgenic, Drugs, Investigational, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.